Table II.

HPV prevalence in selected studies and subgroups.

		No. of patients		Pooled HPV prevalence
Variable	No. of included studies	Summed events	Summed total	Fixed effect model (95% CI)	Random effects model (95% CI)	I2	P-value (Cochrane Q-test)
Ovarian cancer (all cases)
HPV 16/18	41	401	2,394	0.17 (0.15–0.18)	0.07 (0.03–0.15)	86.8	<0.0001
All genotypes	43	555	2,754	0.20 (0.19–0.22)	0.10 (0.05–0.18)	83.8	<0.0001
Ovarian cancer by pathological types
HPV 16/18
Serous	25	75	791	0.09 (0.08–0.12)	0.04 (0.01–0.13)	72.9	<0.0001
Non-serous	23	38	434	0.09 (0.06–0.12)	0.02 (0.01–0.12)	12.5	<0.0001
HPV (all genotypes)
Serous	26	86	791	0.11 (0.09–0.13)	0.06 (0.02–0.16)	74.5	<0.0001
Non-serous	24	47	459	0.10 (0.08–0.13)	0.05 (0.01–0.16)	24.0	<0.0001
Subgroup by region
HPV 16/18
Asia	20	287	1,381	0.21 (0.19–0.23)	0.14 (0.07–0.26)	88.6	<0.0001
Europe	12	90	713	0.13 (0.10–0.15)	0.05 (0.01–0.26)	88.5	<0.0001
HPV (all genotypes)
Asia	21	426	1,691	0.25 (0.23–0.27)	0.20 (0.12–0.32)	83.3	<0.0001
Europe	13	102	763	0.13 (0.11–0.16)	0.05 (0.01–0.26)	88.0	<0.0001

HPV, human papillomavirus; HPV 16/18, HPV 16 and/or 18.